Considering some of the current limitations in adoptive T-cell transfer, we sought to evaluate the phenotypic and functional differences of effectors derived from naive, memory, and tumor-infiltrating CD8+ T cells (NTeff, MTeff, and TILeff, respectively), and to further investigate the possibility of generating optimal tumor-reactive CTLs with high-dose IL-2 activation for application in clinical trials. Here, IL2 is linked to neoplasm.